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Available online 2 April 2016Silent neurotoxicity, a term introduced approximately 25 years ago, is deﬁned as a persistent change to the
nervous system that does not manifest as overt evidence of toxicity (i.e. it remains clinically unapparent) unless
unmasked by experimental or natural processes. Silent neurotoxicants can be challenging for risk assessors, as
the multifactorial experiments needed to reveal their effects are seldom conducted, and they are not addressed
by current study design guidelines. This topic was the focus of a symposium addressing the interpretation and
use of silent neurotoxicity data in human health risk assessments of environmental toxicants at the annualmeet-
ing of the Developmental Neurotoxicology Society (previously the Neurobehavioral Teratology Society) on June
30th, 2014. Several factors important to the design and interpretation of studies assessing the potential for silent
neurotoxicity were discussed by the panelists and audience members. Silent neurotoxicity was demonstrated to
be highly speciﬁc to the characteristics of the animals being examined, the unmasking agent tested, and the be-
havioral endpoint(s) evaluated. Overall, the experimental examples presented highlighted a need to consider
common adverse outcomes and common biological targets for chemical and non-chemical stressors, particularly
when the exposure and stressors are known to co-occur. Risk assessors could improve the evaluation of silent
neurotoxicants in assessments through speciﬁc steps from researchers, including experiments to reveal the mo-
lecular targets and mechanisms that may result in speciﬁc types of silent neurotoxicity, and experiments with
complex challenges reminiscent of the human situation.
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“Silent neurotoxicity”, also called silent toxicity or silent damage
to the nervous system, represents a persistent biochemical change ornue, N.W., Mail Code 8623P,morphological injury to the nervous system that does not induce
overt evidence of toxicity (i.e. remains clinically unapparent) unless
unmasked by experimental or natural processes (Reuhl, 1991;
Grandjean, 2008; Giordano and Costa, 2012). This concept has been
described in association with numerous neurotoxic chemicals and neu-
rodegenerative diseases since its ﬁrst use approximately 25 years ago
(Needleman, 1993; Weiss, 1996; Thiruchelvam et al., 2002; Weiss
et al., 2002; Costa et al., 2004; Cory-Slechta et al., 2005; Barlow et al.,
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broad range of toxicity mechanisms, and therefore be of concern for
many environmental chemicals, it remains poorly understood.
Silent neurotoxicity overlaps with other commonly used terms,
including, perhaps most closely, the “2-hit” or “multiple hit” models
and hypotheses (including the “neurodevelopmental hypothesis”).
Each of these terms describe the occurrence of initial insults that can
alter cellular function and prime a system to either make it vulnerable
to a subsequent insult(s) or progressively lead to loss of normal function
with additional insult(s), with the effects of one insult in isolation being
insufﬁcient to induce disease. These theories are based on studies of
carcinogenesis, but have been more recently applied to nervous system
effects (Nordling, 1953; Armitage and Doll, 1957; Weinberger, 1987;
Bayer et al., 1999). Silent neurotoxicity is also related to the phenomena
of chemical and non-chemical “interactions” (National Research
Council, 2009) and “latent” or “delayed” neurotoxicity (Aldridge et al.,
1969). In general, although there may be slight differences in the appli-
cation of these closely related terms (e.g., emphasis on a period of laten-
cy between exposure and the ability to reveal effects; emphasis on a
developmental insult; limited to speciﬁc types of “unmasking”; etc.),
all of these inter-related concepts are attempting to examine and
describe neurotoxicity in terms of cumulative effects that may be more
relevant to human exposure situations than traditional toxicity testing
for effects of a single chemical measured immediately after exposure.
For silent neurotoxicity, in the context of environmental health, a
factor that “unmasks” toxicity could be any stimulus that challenges or
otherwise adjusts the threshold of a cellular system that is the target
of a particular environmental agent. Some examples of “unmasking”
agentsmay include stress, disease, infection, ormultiple chemical expo-
sures, while related natural processes could include aging or loss of tol-
erance. Although the topic of silent neurotoxicity does not represent a
new concept (Reuhl, 1991), it is one that persists in the neurotoxicology
literature (Giordano and Costa, 2012). Despite the attention given to
this topic, our current understanding of the different causes for silent
neurotoxicity remains incomplete. While recent research continues to
unravel the molecular targets that may be involved for certain types of
insults, which is expected to improve our understanding of themolecu-
lar mechanisms of developmental neurotoxicity and help to move the
ﬁeld forward (e.g., via construction and sharing of common adverse
outcome pathways (Ankley et al., 2010)), identifying potential silent
neurotoxicants remains difﬁcult for risk assessors.
This topic was the focus of a symposium held on June 30th, 2014 at
the 38th annualmeeting of the Developmental Neurotoxicology Society
(previously the Neurobehavioral Teratology Society) held in Bellevue,
WA from June 28th–July 2nd. The symposium was organized into a
series of presentations followed by a facilitated panel discussion with
the audience, which was comprised of academicians, federal and state
government scientists, industry scientists, and non-government organi-
zation representatives. The intent of the discussionwas to provide infor-
mation useful to risk assessors, who often ﬁnd these data (particularly
data related to behavioral changes) difﬁcult to incorporate into their
neurotoxicity hazard descriptions. It is clear that the appropriate inter-
pretation of experiments capable of revealing silent neurotoxicity
would also be of critical use to decision-makers considering cumulative
risk assessment (i.e. the combined risk frommultiple agents or stressors,
including chemical mixtures as well as non-chemical stressors) and
environmental justice scenarios (e.g., improving the decisionmaker's as-
sessment of effects from disproportionate exposure in low income com-
munities by effectively identifying the most vulnerable subpopulations),
two key areas of current interest in the risk assessment ﬁeld.
From a risk assessment vantage-point, the potential for silent neuro-
toxicity is concerning for a number of reasons. First, because these types
of experiments can be difﬁcult to perform, they are seldom found in the
published literature and, when available, they are often focused on nar-
rowly deﬁned, speciﬁc research questions that can be difﬁcult to extrap-
olate to broader exposure scenarios or populations being investigatedby the risk assessors. Additionally, experimental animal studies con-
ducted according to guideline protocols (e.g., a developmental toxicity
study), which may be viewed as the most desirable studies available
for use in risk assessments due to factors such as their use of standard-
ized endpoints and large group sizes, are not designed to detect these
types of effects. Taken together, the fact that the overwhelmingmajority
of studies used in risk assessments do not consider multiple insults, or
“challenges”, in a single model has the potential to result in an under-
representation of the true potential for developmental neurotoxicity in-
duced by the substance(s) under evaluation. For environmental agents
that only exhibit toxicity in the presence of another chemical or non-
chemical stressor, if experimental unmasking challenges were not
examined, then a neurotoxicity hazard could be considered unlikely
based on evidence collected under basal conditions. Since every
human exposure scenario involves both chemical and non-chemical
stressors, with the right combination the chemical might exhibit effects
that wouldn't be identiﬁed by experimental studies testing for effects in
isolation. Similarly, effects that appear to be “reversible” (i.e. pheno-
types that appear to be associated with the presence of the causal
agent in the body) may not be used for derivation of toxicity values,
even though these agents may have additional latent effects observed
only with unmasking. In addition to laboratory-based toxicology exper-
iments, silent neurotoxicity also poses a difﬁculty for epidemiologic
studies. For instance, it might be problematic to link an observed apical
effect back to a particular chemical exposure if the investigator does not
speciﬁcally examine effect modiﬁcation by the unmasking stimuli
revealing the response (e.g., age; other chemical exposures). Finally, a
lack of data examining silent neurotoxicity increases the possibility of
assessors providing an incomplete description of potentially sensitive
subpopulations and lifestages, such as childrenwho experienced prena-
tal maternal stress (e.g., acute or chronic distress during pregnancy that
may result fromemotional or physical trauma to themother) or individ-
uals exposed to a complex mixture containing both the contaminant in
question and other agents capable of unmasking neurotoxicity. Overall,
this continues to represent a critical and controversial topic for neuro-
toxicity risk assessment.2. Summary and critical messages from the
symposium presentations
Dr. Aschner introduced the topic by presenting human data from
methylmercury (MeHg) poisonings in Minamata, Japan (contaminated
ﬁsh) and Iraq (contaminated grain). He reﬂected that exposed victims
consistently exhibited a long latent period of weeks to months (or lon-
ger) after exposure ended before the onset of behavioral symptoms
(Grandjean et al., 1998;Myers et al., 2000; Castoldi et al., 2003). Initially,
these latent effects were hypothesized to be due to the slow accumula-
tion of a toxic metabolite, iHg (inorganic mercury), which would vary
across individuals depending on their metabolism, and which would
be expected to correlate inversely with latency. One would expect the
buildup of iHg to be faster at higher levels of MeHg exposure, resulting
in a shorter latency period. However, this is not substantiated by the
data, with patients experiencing higher MeHg exposure levels failing
to show shorter latency periods (Weiss et al., 2002). Interestingly, in
at least some cases, the onset of different behavioral phenotypes was
shown to occur with different latencies (e.g., visual constriction could
be manifest several months after ataxia). While this may illustrate pro-
gressive injury to a single cellular system, which seems unlikely for the
example above at least, it is probably more likely that this disparity
reﬂects differences in the time-dependence for clinically manifest
changes due to effects at differentmolecular targets, including the dopa-
mine and GABA neurotransmitter systems (Newland et al., 2008). It is
also possible that the rate of conversion of MeHg to iHg is rate-limited
and therefore iHg is constantly generated at a rate independent of the
level of MeHg; however, the literature does not support the underlying
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(Magos et al., 1985).
This latency requirement for observations of behavioral neurotoxic-
ity illustrated the need for risk assessors to keep inmind the complexity
of human disease, a topic picked up by Dr. Cory-Slechta. Dr. Cory-
Slechta emphasized that human disease is a consequence of multiple,
co-occurring risk factors across time. She urged researchers to consider
the use of behavioral measures common to human scenarios, as com-
plex andmultifactorial tests are likely to best represent the human con-
dition. A research-speciﬁc example she provided loosely equated ﬁxed
interval performance testing to the typical human scenario of studying
for an exam, and cramming as the exam approaches. Dr. Cory-Slechta
also emphasized that it is essential to consider common adverse out-
comes and common biological targets for chemical and non-chemical
stressors, particularly when these insults are known to co-occur. For in-
stance, both lead toxicity and prenatal stress appear to target the
hypothalamic-pituitary-adrenal (HPA) axis and the mesocorticolimbic
system, which partly mediate cognition and attention (Piazza et al.,
1996; Cory-Slechta et al., 1998). This type of consideration led to a series
of studies by Dr. Cory-Slechta on the effects of lead and prenatal stress
on these systems and behaviors. This idea of conserved molecular or
cellular targets for the various chemical challenges and stressors en-
countered by an organism at different stages of development was also
highlighted during presentations by Drs. Aschner and Caudle, and Dr.
Bilbo similarly described the concept of “2-hits” to the same target(s).
Drs. Aschner and Caudle described the common idea of stress or insults
during development causing a change in the vulnerability or trajectory
to disease in the adult organism. They discussed how early develop-
mental insults could change the threshold for the onset of symptoms
(i.e. Parkinson's disease (PD)-like symptoms) by causing a subclinical
change in the neural cells (i.e. dopaminergic neurons) or neurochemis-
try involved. They noted that subclinical developmental modiﬁcations
might accelerate the trajectory of normal, later-life disease states, or in-
crease the vulnerability of certain systems to future unmasking insults
which are then able to overcome the plasticity-related responses of
the brain (Richardson et al., 2006; Richardson et al., 2008; Racette
et al., 2012). Dr. Cory-Slechta suggested a similar idea in that early ad-
verse behavioral conditions may be associated with a less resilient,
more vulnerable phenotype leading to a sensitive system. In the context
of environmental justice, these lines of research might help to identify
early changes in subpopulations of disadvantaged communities that
may be at increased risk of neurotoxicity with chemical exposure later
in life.
The variable range of potential unmasking agents that might be rel-
evant to assessing silent neurotoxicity was apparent when looking
across the presentations. Experiments by Drs. Cory-Slechta and Bilbo
both demonstrated that behavioral changes related to anxiety and
cognitionwere sometimes only affected by the combination of exposure
to an environmental toxicant (i.e. lead, MeHg or air pollution) and ex-
perimentally induced early life stress (i.e. prenatal nest restriction or
immobilization) in rodents (Cory-Slechta et al., 2008; Bolton et al.,
2013; Weston et al., 2014a). Dr. Aschner demonstrated that differences
in genetic susceptibility may inﬂuence the likelihood of observing latent
neurotoxicity in a Caenorhabditis elegans (C. elegans) model of PD
(Bornhorst et al., 2014; Chen et al., 2015), while Dr. Caudle showed
that exposure to one potential dopaminergic toxicant throughout
gestation and lactation- the chlorinated organophosphate ﬂame
retardant, Tris (1,3-dichloroisopropyl)phosphate (TDCPP), can modify
the vulnerability of the adult dopamine system to toxicity caused by
exposure to a second chemical toxicant, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), in adulthood (unpublished results). In Dr.
Caudle's “2-hit” model, the animals exhibited an increased vulnerability
to MPTP, with developmental TDCPP exposure enhancing the decreased
locomotion and striatalmarkers of dopaminergic neuron function caused
by MPTP, which is consistent with published results from his lab using
endosulfan (Wilson et al., 2014). Dr. Bilbo also illustrated how postnatalchanges in diet (i.e. a high-fat diet) can unmask neurotoxic changes
caused by gestational exposure to air pollution (Bolton et al., 2014). An
important point made throughout these presentations is that the type
of unmasking agent matters. The data indicate that different types of
unmasking agents (e.g., social; chemical; physical) may be required to
elicit neurotoxicity in a chemical- and target system-speciﬁc manner.
Therefore, not observing silent neurotoxicity after chemical exposure
using a single stressor and a single behavioral measure does not mean
that the same chemical exposure would not result in toxicity if another
behavior or stressor was tested. Further, it should be recognized that
evenwhen different unmasking agents appear to act on the same system
or molecular target, it is possible that they will unmask silent neurotox-
icity in disparate ways.
Another interesting phenomenonwas raised in the presentations by
Drs. Cory-Slechta and Bilbo. These researchers observed a clear differ-
ence in sensitivity to silent neurotoxicity across sexes, which was de-
pendent on the speciﬁc combination of chemical exposure, unmasking
agent, and behavioral test(s) employed. Using prenatal exposure of
mice to diesel exhaust particles (DEPs), Dr. Bilbo showed that DEP
alone doesn't impact adult anxiety tested in a zero maze, but DEP with
nest restriction stress to the dams increased measures of anxiety in
fear conditioning and zero maze assays of the offspring (Bolton et al.,
2013). In all of these experiments, the female pups were noticeably
less vulnerable than the male pups in the behavioral assays. When Dr.
Bilbo applied a second paradigm, namely prenatal DEP and postnatal
administration of a high fat diet as an unmasking agent, once again
the male pups, but not the female pups, were vulnerable, exhibiting in-
creased anxiety at four weeks of age (Bolton et al., 2014). Interestingly,
in Dr. Cory-Slechta's experiments employing developmental exposure
to either lead or methylmercury, and a different paradigm of develop-
mental stress as an unmasking agent (i.e. maternal stress induced by re-
straint), sex-dependent responses were also observed; however, in
these experiments, effects on higher cognitive function were generally
manifest in the female pups, not the male pups (Weston et al., 2014a;
Weston et al., 2014b). It is unknown whether these differences in vul-
nerability across sexes are attributable to the different environmental
chemical exposures, the different unmasking challenges, the different
behavioral test paradigms, or some combination of these variations
across experiments. Regardless, the data strongly suggest a need for ex-
amination of both sexes when evaluating the potential for silent neuro-
toxicity, similar to sentiments in related neuroscience research ﬁelds
(e.g., (Beery and Zucker, 2011)).
Molecular changes which may be detectable prior to overt manifes-
tations of neurotoxicity (e.g., during the latent period) is a critical area of
ongoing and future research. Although these early events are often
adaptive in nature, an increasedunderstanding of the temporal progres-
sion of underlying neurobiological changes could eventually yield pre-
dictive insight. For the particular toxicants and endpoints discussed by
the presenters, common molecular changes included alterations to the
HPA axis, inﬂammation-related responses and oxidative stress. Dr.
Aschner discussed early life MeHg exposure in a C. elegansmodel rele-
vant to PD. The combination of exposure and knockout of pdr-1, a ho-
mologue to the human parkin gene, resulted in increased reactive
oxygen species (ROS), which he hypothesized could be related to the
later life neurotoxicity observable in this model (Chakraborty et al.,
2015). Similarly, using in vivo and in vitro rodent models related to
PD, Dr. Caudle observed suggestive associations between oxidative
stress-related events and the development or progression of neurotox-
icity (Caudle et al., 2007). Drs. Bilbo and Cory-Slechta both observed an
association between altered HPA axis function and altered behavior. Dr.
Bilbo observed that, in response to nest restriction, the male pups, but
not the female pups, exhibited increased corticosterone (Bolton et al.,
2013). Notably, the male pups were selectively vulnerable (i.e. only
male pups exhibited impaired cognition) in these experiments. Dr.
Cory-Slechta was also able to detect increased corticosterone in the
blood, which was correlated with other molecular evidence of nervous
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dihydroxyphenylacetic acid (DOPAC), in the prefrontal cortex (Cory-
Slechta et al., 2010). Inﬂammation may also be complicit in these
types of changes. The vulnerable male pups in Dr. Bilbo's experiments
combining nest restriction and DEP exposure exhibited increased evi-
dence of inﬂammation, such as increased expression of toll-like receptor
4 and caspase-1, whereas the female pups actually exhibited increased
expression of anti-inﬂammatory interleukin 10 (Bolton et al., 2013).
Additionally, the combination of exposure and dietary stress caused
morphological and molecular markers of activation of microglia in the
hypothalamus of the male, but not female, offspring. Dr. Bilbo went on
to show that this increased mononuclear cell activation in the brain
was, at least in part, due to macrophage inﬁltration into the brain, sug-
gesting that there may be a linkage between changes in the adipose
tissue and neuroinﬂammation in the brain (Bolton et al., 2014). Given
these data and other similar ﬁndings emerging in the literature, the
potential role for neuroimmune interactions and low level oxidative
stress-induced changes in the development of silent neurotoxicity
deserves additional study.
Several speakers brieﬂy touched upon the issue of dose-response re-
lationships for effects related to silent neurotoxicity. Dr. Cory-Slechta
reminded the audience that not all stress is negative. She illustrated
that the physiological response to some stressors often involves some
adaptation or resilience at lower concentrations, which is overcome at
higher concentrations. Dr. Aschner discussed a similar concept, noting
that adaptive measures initiated in response to exposure during devel-
opment typically engender short term beneﬁts, such asmaking an indi-
vidual better prepared to respond to an adverse environment. These
presenters noted how non-monotonic responses are common, not
only for measures of behavior, as one might expect, but also for the un-
derlying neurochemical changes. Dr. Cory-Slechta illustrated this using
exposure to MeHg and prenatal stress as an example, with offspring
exhibiting non-monotonic changes in dopamine and serotoninmetabo-
lites, which differed by sex and brain region analyzed (Weston et al.,Fig. 1. Hypothetical effects of developmental exposure and unmasking stimulus on lifetime neu
two theoretical sets of neurons, namely those responsible for sensory function (solid red line) a
neurons undergo a prescribed, programmatic increase in functional marker(s) reﬂecting the de
could theoretically include region-speciﬁc changes in neuron number, neurotransmitter levels, a
of functional marker levels necessary for “normal” behavior is illustrated (gray shading), with a
Perinatal exposure to a toxicant for a brief time prenatally and postnatally (dashed black line) re
higher cognitive function (dashed blue line). If this perinatal exposure is combinedwith exposu
function: dotted red line; for higher cognitive function: dotted blue line). This conceptual illustr
10.1037/0003-066X.56.1.5), with modiﬁcations based on reviews by Landrigan et al. (2005) an2014a). Interestingly, neurochemical alterations were observable in
both sexes, even though only the females demonstrated behavioral
changes, perhaps reﬂecting an increased resiliency of the associated
system(s) inmales. In addition to considering the potential for additiv-
ity of toxicants focused on the same biological system, Dr. Caudle
emphasized that it is also important to recognize that these re-
sponses should not be expected to exhibit linear functions.
Across these presentations, measurements of changes in behavior
thatmight be associatedwith silent neurotoxicity were shown to be de-
pendent on a diverse set of variables. Previous work has demonstrated
that stimuli during speciﬁc, sensitive periods of early life can have per-
manent consequences (e.g., Godfrey and Barker, 2001). Central nervous
system (CNS) structures and functions undergo programming across
various stages of embryonic, fetal, and early postnatal development
(Selevan et al., 2000; Semple et al., 2013). This developmental program-
ming determines the set points of physiological and metabolic re-
sponses in adult life. Depending on the timing, duration, and toxicant
type, chemical exposure may lead to developmental adaptations
(e.g., changes to CNS hormones or neurotransmitters; alterations in
neuronal proliferation or migration) that readjust developmental set
points. As many of these set points are governed by the anatomical
location of the target cells, or in response to genes that are only
expressed during a limited developmental window, this raises addition-
al possibilities related to brain region-speciﬁc vulnerability andpotential
differences in genetic susceptibility for different silent neurotoxicants.
Due to the adaptability of the developing CNS, alterations in speciﬁc
neuronal nuclei may not result in an overt change in phenotype during
development. Yet, these same changes may predispose the adult to ab-
errant physiological functions and increased risk of disease as the CNS
is further challenged, either with normal aging or by other unmasking
agents.
Fig. 1 attempts to illustrate some of the concepts that are likely to
be important for neurotoxicity risk assessors to consider. In this simpli-
ﬁed example, hypothetical changes in undeﬁned functional markersrological function. This schematic illustrates the potential lifetime functional trajectory of
nd those responsible for higher cognitive function (solid blue line). Over time, both sets of
velopment of those speciﬁc behaviors until some optimal level is achieved. These markers
nd/or synapse number or dendritic spine density (or othermarkers). A hypothetical range
theoretical threshold belowwhich “abnormal” behaviors are observable (orange shading).
sults in an eventual change in the trajectory of both sensory function (dashed red line) and
re to an unmasking stimulus in late infancy, this trajectory is further modiﬁed (for sensory
ation is adapted primarily from concepts presented in Thompson and Nelson (2001) (doi:
d Catts et al. (2013).
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types are shown. For both behaviors, although the speciﬁc timing and
magnitude of the trajectories differ, the functional markers are depicted
as increasing up until at least early school age, with lesser increases
through adolescence, after which the markers plateau and eventually
decline at later ages. Although a wide range for “normal function” is il-
lustrated, depending on the marker(s), optimal function could be
achieved at the lower end of that range (e.g., for a marker such as syn-
apse number, synaptic reﬁnement and experience-dependent learning
would be expected to result in a smaller number of stronger synaptic
connections). Likewise, while the ﬁgure depicts a theoretical threshold
in the functionalmarkers belowwhich clinically apparent abnormalities
in behavior can be detected, excesses or overactivation of some nervous
system components, and not just decrements, can also indicate toxicity.
In Fig. 1, exposure to an undeﬁned toxicant during the perinatal period
has a more robust effect on the trajectory of one phenotype (i.e. higher
cognitive function; trajectory after exposure shown as dashed blue
lines) than the other (i.e. sensory function; trajectory after exposure
shownasdashed red lines). In addition to the speciﬁc behavioral pheno-
type assessed, this ﬁgure illustrates that time after exposure, or aging, is
important to consider as a second variable in this comparison since ab-
normalities in either function are not observed directly after exposure.
As the exposed subjects begin to age, it appears likely that an experi-
menterwill be able to detect abnormalities in higher cognitive function,
whereas declines in sensory function induced by exposure are not ro-
bust and abnormalities are not apparent until old age, making detecting
these effects more difﬁcult. This difference in sensitivity is assumed to
be dependent not only on the target system(s) of the toxicant, but
also on the timing (andpossibly duration) of exposure. In Fig. 1, the con-
cept of experimental unmasking is illustrated by introduction of an un-
deﬁned unmasking agent sometime during infancy, with unmasking in
the absence of perinatal exposure not causing any changes in the trajec-
tory of these behaviors (not illustrated in Fig. 1). Again, depending on
the type and timing of this unmasking insult, effects on one function
or with one type of chemical exposure may be different from other sce-
narios. In this illustration, both sensory function and higher cognitive
function are sensitive to this particular unmasking, resulting in an earli-
er onset of observable abnormalities for both functions. Again, the
timing at which the behaviors are measured after unmasking is critical.
For example, following the combination of exposure and unmasking,
measuring sensory function at 5 years of agewould reveal no abnormal-
ities, whereas assessing sensory function at 20 years of agewould reveal
this silent toxicity. This simpliﬁed ﬁgure fails to capture the potential
impact of several other important variables, including profound differ-
ences in sensitivity due to interindividual variations (e.g., across sexes
or genetic backgrounds), exposure level-dependent differences in how
the functional trajectories are altered, or possible biphasic-type re-
sponses to unmasking (e.g., adaptive responses to low levels of stress
which might actually attenuate the declining trajectory caused by peri-
natal exposure). In all, researchers and risk assessors could beneﬁt from
considering the potential inﬂuence of a complex and diverse range of bi-
ological variables when designing and interpreting experiments related
to silent neurotoxicity.
3. Discussion and considerations for future efforts
This discussion is framed around a series of topics discussedwith the
audience during a panel session at the symposium. Some common
themes were raised during the speaker presentations, including consis-
tent ﬁndings of sex-related differences in themanifestation of latent be-
havioral responses and the potential involvement of inﬂammation-
related and/or oxidative stress-related responses as mechanistic events
leading to the development of these phenotypes. All of the panelists
discussed silent neurotoxicity as clearly adverse and of signiﬁcant con-
cern for the purposes of human health risk assessment, and they
noted that traditional methods generally do a poor job of revealing it.As a result, this might raise a public health concern that adverse
neurodevelopmental effects could be going undetected for environ-
mental agents assessed based on traditional toxicity studies. However,
the relative difﬁculty of measuring neurotoxic effects that can remain
clinically undetectable for months or even years after exposure high-
lights the need not only for increased testing for such effects, but also
for approaches to prioritize testing of agents that might be viewed as
more likely to cause this form of toxicity (e.g., based on observations
from structurally related chemicals; for chemicals with substantial
human exposures at developmental ages established as periods during
which regions of the nervous system are sensitive to lasting changes
in structure and/or function). Although silent neurotoxicity has consis-
tently received attention in the past scientiﬁc literature (Reuhl, 1991;
Bondy and Campbell, 2005; Grandjean, 2008; Giordano and Costa,
2012), itmay be that current and future advances in behavioral andmo-
lecular methods could position neurotoxicologists to make signiﬁcant
inroads towards identifying, describing, and possibly predicting these
types of neurotoxicity in a manner that is more useful for risk assessors.
Asmethods for identifying and predicting silent neurotoxicity caused by
environmental agents are advanced, it is important to keep in mind the
lessons learned during the development of related theories (e.g., the “2-
hit”, neurodevelopmental hypothesis for schizophrenia; (Weinberger,
1996)). It is notable that, while the application of the “multiple hit”
theory to nervous system effects, for schizophrenia in particular, has
now gained wider acceptance, it was initially met with criticism and
sparked controversy. The controversywas primarily a result of inconsis-
tencies in individual study ﬁndings and an initial inability to plausibly
link neurodevelopmental abnormalities to clinical symptoms after a
delay of decades; more recent studies have strengthened the coherence
of the ﬁndings (Weinberger, 1996).
The panelists felt it important to conveyhow littlewe still understand
about silent neurotoxicity. There are some data which begin to describe
the potential use of markers of inﬂammation or immune response
(e.g., cytokines such as interleukin-6), glial activation, or markers of oxi-
dative stress, to detect early changes thatmight be associatedwith silent
neurotoxicity. For example, recent publications from two of the panelists
suggest that changes in microglial- and/or astrocyte-speciﬁc proteins
can be observed in those exposure groups and sexes demonstrating
changes in behavior due to a combination of chemical and nonchemical
challenges (Allen et al., 2014; Bolton et al., 2014). Interestingly, these
alterations were dependent on both the brain region(s) and
behavior(s) being examined. However, the data, and our ability to inter-
pret what these data indicate, are far from complete. In particular, the
temporal progression of these preliminary associations (e.g., whether
early changes in neuroinﬂammatory markers might predict future vul-
nerability to a subsequent neurotoxicant challenge) has not yet been ex-
amined. Given the biological complexity of these types of responses, it is
unlikely that risk assessors will have data sufﬁcient to provide a clear
mechanistic understanding of any observed changes. Thismay be impor-
tant to keep in mind when drawing conclusions regarding, for example,
the consistency or dose-dependency of the data. For example, evidence
for behavioral changes in only one sex, or at only one exposure level,
or at only one time point, with data indicating these behaviors are not
changed when these conditions are varied, should not necessarily be
viewed as inconsistent or in conﬂict. In such cases, it is important to care-
fully consider both the strength of the evidence (e.g., replicated ﬁndings
would be interpreted with greater conﬁdence) and whether methodo-
logical differences may exist to explain discrepancies across studies.
While an understanding of the mechanism(s) for toxicity can aid inter-
pretation, lack of a mechanistic explanation for what might be a very
complicated biological association is generally not reason enough to dis-
count these types of ﬁndings. Unfortunately, we do not currently have
any molecular, morphological, or behavioral features that risk assessors
could use as effective indicators or biomarkers for when particular
types of silent damage have occurred. As previously noted by Giordano
and Costa (2012), knowledge regarding potential mechanism(s) of
43A.D. Kraft et al. / Neurotoxicology and Teratology 55 (2016) 38–44developmental neurotoxicity would help aid the understanding of silent
neurotoxicity, although it is important to recognize that these authors
also noted that this knowledge is not a requirement for risk assessment.
It is clear that traditional test guidelines are generally incapable
of revealing or detecting these types of effects. The panelists argued
that there is a need for toxicologists to better consider the intricacies
of human neurotoxicity, both in the context of exposure and co-
occurring risk factors aswell as the complexity of human behavior. Sim-
ilarly, risk assessors were encouraged to pay particular attention to the
study-speciﬁc parameters thatmight inﬂuence the detection sensitivity
(or lack thereof) of a particular experiment. These parameters include
the timing of exposure and latency before behavioral testing, the types
and timing of unmasking challenges, whether the speciﬁc characteris-
tics of the experimental animals encompass potentially-vulnerable pop-
ulations, and how well the behavioral assays serve to investigate a
diverse array of human behaviors. Generally, to reveal silent neurotox-
icity, experiments should be designed in such a way that they are capa-
ble of challenging or pushing the threshold for a particular response of
the system, such that modest effects on that system (e.g., capacity-
changing effects due to exposure) have the potential to be revealed.
As these types of studies becomemore commonplace, continued discus-
sion and coordination between neurotoxicology researchers and risk as-
sessors (e.g., through training opportunities or collaborations on test
design and interpretation) may help to reduce uncertainties related to
evaluating the potential for silent neurotoxicity in human health risk as-
sessments of environmental toxicants. However, given the complexity
of these experiments, both in conduct and interpretation, there is a
future need to better clarify the signals or situations that might suggest
an elevated concern for potential silent neurotoxicity.
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